CeriBell Inc. (CBLL) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CBLL scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 8 / 20. Per the RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -3.89%. For a prospective investor, the cash engine is the weakest link: the company is not currently generating returns on invested capital or free cash flow to support the valuation.
• Whale 13F Flow: 16 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and suggests some institutional interest, though the source data does not itemize 13F holders (see Analyst View section).
• Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider conviction signals in the data.
• Macro Regime Fit: 7 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market; the low score reflects limited regime-based support.
• Forensic Balance Sheet: 11 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 14.75, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5. The balance sheet is a relative bright spot, though the Piotroski score is mid-range.

Taken together, the investor implication is that the stock's recent price strength (52-week range of $10.85 to $28.19, with the current price of $27.82 near the top of that range) is not supported by the operating cash-flow fundamentals as measured in the RQD framework. Valuation tradeoffs are significant: with no reported P/E or EPS in the source data, the investor cannot benchmark the price against earnings. Upside drivers in the data are limited to institutional positioning and the balance-sheet strength; downside risks center on sustained cash burn and the distribution warning verdict.

Per the company profile, CeriBell Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the market data, the company reports a gross margin of 87.9%. Not available in source data for specific products, customers, or revenue-generation detail beyond the reported financial lines.

Per the SEC financials, revenue grew from $45.2M (FY 2023) to $65.4M (FY 2024) to $89.1M (FY 2025), while operating losses widened from $-30.0M to $-39.7M to $-58.4M. Per the market data, the operating margin and net margin are both -60%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 14.75 and the Piotroski F-Score is 4/9, with a Debt/Equity ratio of 0.5. Reported cash declined from $194.4M (FY 2024) to $40.5M (FY 2025).

Per the news wire, recent headlines reference an FDA clearance for CeriBell and a one-year share price run of 133%, with multiple outlets questioning whether the stock is fully priced. All six items are tagged YELLOW with a "MARKET WIRE" impact label. Key catalysts: FDA clearance (per headline references). Risk watch items: valuation concerns raised across multiple headlines. Per the Butterfly Supply-Chain Graph, there are no proprietary signals in the source data.

• What drives the FY 2025 cash decline from $194.4M to $40.5M, and what is the company's runway at the reported FY 2025 FCF of $-41.6M?
• What are the reported EPS, P/E, and EV/EBITDA figures, which are absent from the source data?
• Which institutional holders and insiders account for the Whale 13F and Insider Conviction pillar scores?
• What is the debt balance behind the reported Debt/Equity ratio of 0.5, since debt is listed as N/A for all periods?
• What is the commercial significance of the FDA clearance referenced in the news wire, and how does it translate into revenue?